Disease Detail

Profile Responses 0
Clinical Trials 154

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Therapy	Indication/Tumor Type	Response Type	Profile Response Detail

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT00084695	Phase II	Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone	Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases	Unknown status	USA	0
NCT00129740	Phase II	Nilotinib	Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)	Completed	USA	0
NCT00471497	Phase III	Nilotinib Imatinib	A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENESTnd)	Completed	USA \| TUR \| SWE \| SVK \| POL \| NOR \| NLD \| ITA \| HUN \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| ARG	13
NCT00513474	Phase I	Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide	Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant	Completed	USA	0
NCT00573378	Phase II	Imatinib + Interferon alpha-2b Interferon alpha-2b + Nilotinib	Imatinib or Nilotinib With Pegylated Interferon-alpha2b in Chronic Myeloid Leukemia	Terminated	USA	0
NCT00602693	Phase I	Sirolimus Allopurinol + Cyclophosphamide + Fludarabine	T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer	Completed	USA	0
NCT00679536	Phase Ib/II	anti-thymocyte globulin + Busulfan + Fludarabine	Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors	Unknown status	USA	0
NCT00720785	Phase I	Bortezomib	Natural Killer Cells and Bortezomib to Treat Cancer	Completed	USA	0
NCT00777036	Phase II	Dasatinib	A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib	Active, not recruiting	USA \| ROU \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| AUS \| ARG	6
NCT00857389	Phase II	Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate	Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies	Completed	USA	0
NCT01077544	Phase I	Nilotinib	A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)	Completed	NLD \| ITA \| GBR \| FRA	0
NCT01188889	Phase Ib/II	Everolimus + Imatinib	RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease	Withdrawn	USA	0
NCT01244750	Phase I	Imatinib Dasatinib Nilotinib	Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting	Completed	USA \| NLD \| ITA \| FRA \| ESP \| DEU	2
NCT01251575	Phase II	Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus	Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant	Completed	USA \| DNK	0
NCT01316250	Phase II	Imatinib Nilotinib	Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia	Recruiting	LBN	0
NCT01397734	Phase I	Arsenic trioxide	Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)	Terminated	USA	0
NCT01498445	Phase Ib/II	Dasatinib + Decitabine	An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)	Terminated	USA	0
NCT01570868	Phase II	Ponatinib	Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)	Terminated	USA	0
NCT01592370	Phase Ib/II	Nivolumab Daratumumab + Nivolumab Daratumumab Ipilimumab + Nivolumab Daratumumab + Dexamethasone + Nivolumab + Pomalidomide Lirilumab + Nivolumab	An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma	Completed	USA \| POL \| ITA \| GRC \| FRA \| BEL	0
NCT01593254	Phase II	Imatinib Dasatinib	Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN)	Completed	USA \| POL \| ITA \| HUN \| FRA \| ESP \| CZE \| CAN \| BRA \| BEL \| AUT \| ARG	3
NCT01606579	Phase Ib/II	Cytarabine + PRI-724 Dasatinib + PRI-724 PRI-724	Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies	Completed	USA	0
NCT01621477	Phase II	Plerixafor Tacrolimus Mycophenolate mofetil anti-thymocyte globulin + Busulfan + Clofarabine Cyclophosphamide + Cytarabine	T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant	Terminated	USA	0
NCT01634217	Phase I		Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation	Completed	USA	0
NCT01640301	Phase Ib/II	Aldesleukin WT1 sensitized T cells	Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant	Terminated	USA	0
NCT01660906	Phase III	Dasatinib	This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib	Completed	USA \| ITA \| FRA \| DEU	1
NCT01698905	Phase II	Nilotinib	Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) (ENESTop)	Active, not recruiting	USA \| POL \| ISR \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG	5
NCT01702064	Phase I	Nilotinib + Ruxolitinib	Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients	Completed	USA	0
NCT01744665	Phase II	Nilotinib	Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5. (ENESTgoal)	Completed	USA	0
NCT01746836	Phase II	Ponatinib	Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib	Recruiting	USA	0
NCT01746849	Phase II	Leuprolide Cyclophosphamide Thiotepa Palifermin	Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation	Active, not recruiting	USA	0
NCT01751425	Phase II	Ruxolitinib	Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)	Terminated	USA	0
NCT01776723	Phase II	Ruxolitinib	A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib	Completed	USA	0
NCT01784068	Phase II	Nilotinib	Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients (ENESTfreedom)	Active, not recruiting	USA \| SWE \| POL \| NLD \| ITA \| IRL \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| BGR \| BEL \| AUT \| ARG	2
NCT01822509	Phase I	Ipilimumab + Nivolumab	Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant	Completed	USA	0
NCT01823198	Phase Ib/II	Methotrexate anti-thymocyte globulin + Busulfan + Fludarabine Tacrolimus Filgrastim	Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies	Completed	USA	0
NCT01829971	Phase I	MRX34	A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection	Terminated	USA	1
NCT01844765	Phase II	Nilotinib	Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.	Completed	USA \| TUR \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP	5
NCT01850004	Phase II	Dasatinib	Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response	Completed	USA \| ITA \| FRA \| ESP \| DEU \| CAN	0
NCT01885897	Phase Ib/II	Nogapendekin alfa inbakicept	IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT	Completed	USA	0
NCT01892371	Phase Ib/II	Azacitidine + Quizartinib Cytarabine + Quizartinib	Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Completed	USA	0
NCT01903733	Phase I	Bosutinib	Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008	Completed	USA \| TUR \| POL \| NLD \| LVA \| ITA \| HUN \| GBR \| FRA \| FIN \| ESP \| CAN \| BRA \| BEL \| AUS \| ARG	13
NCT01914484	Phase II	Nilotinib + Ruxolitinib	Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia	Completed	CAN	0
NCT01926587	Phase Ib/II	Azacitidine + Regorafenib	Oral Rigosertib in Combination With Azacitidine	Completed	USA \| FRA	0
NCT02011945	Phase I	Dasatinib + Nivolumab	A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia	Completed	USA \| ITA \| FRA \| ESP \| DEU \| CAN \| AUS	0
NCT02047149	Phase I	Dasatinib + Zileuton	Evaluating the Safety of Zileuton (Zyflo(R)) in Combination With Dasatinib (Sprycel (R) in Chronic Myelogenous Leukemia	Terminated	USA	0
NCT02081378	Phase I	Asciminib Asciminib + Imatinib Asciminib + Dasatinib Asciminib + Nilotinib	A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL	Completed	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| AUS	3
NCT02091245	Phase I	Selinexor	Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML	Active, not recruiting	USA	0
NCT02092324	Phase II	Ruxolitinib	Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia	Completed	USA	0
NCT02115295	Phase II	Cladribine + Cytarabine + Idarubicin Midostaurin	Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML)	Recruiting	USA	0
NCT02130557	Phase III	Bosutinib Imatinib	A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia	Completed	USA \| SWE \| SVK \| POL \| NOR \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CAN \| BEL \| AUS	7
NCT02200380	Phase II	Plerixafor CDX-301	A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs	Terminated	USA	0
NCT02203903	Phase I	MultiTAA-specific T cells	Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE)	Recruiting	USA	0
NCT02208037	Phase II		Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)	Completed	USA	0
NCT02225574	Phase Ib/II	Binimetinib + Nilotinib	An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)	Terminated	USA	0
NCT02228382	FDA approved	Bosutinib	Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors	Terminated	USA \| SWE \| NOR \| ITA \| FRA \| ESP \| DEU \| AUT	0
NCT02268370	Phase II	Dasatinib	Treatment-free Remission Accomplished With Dasatinib in Patients With CML (TRAD)	Unknown status	CAN	0
NCT02311998	Phase Ib/II	Bosutinib + Inotuzumab ozogamicin	Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML	Completed	USA	0
NCT02326311	Phase III	Dasatinib Nilotinib Imatinib	Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients >=60 Years in Deep Molecular Response	Completed	ITA	0
NCT02353728	Phase II	Nilotinib	Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy	Completed	USA	0
NCT02381548	Phase I	Adavosertib + Belinostat	Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia	Terminated	USA	0
NCT02467270	Phase II	Ponatinib	Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses	Active, not recruiting	USA \| SWE \| POL \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| AUS \| ARG	7
NCT02487459	Phase I	Rivogenlecleucel Rimiducid	Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies	Withdrawn	USA	0
NCT02530034	Phase I	Hu8F4	Hu8F4 in Treating Patients With Advanced Hematologic Malignancies	Active, not recruiting	USA	0
NCT02556931	Phase II	Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus	Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies	Completed	USA	0
NCT02602314	FDA approved	Imatinib Nilotinib	Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia (SUSTRENIM)	Unknown status	NLD \| ITA	0
NCT02629692	Phase Ib/II	K0706	Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to >=3 Prior CML Therapies	Active, not recruiting	USA \| TUR \| ROU \| ITA \| HUN \| GBR \| FRA \| ESP \| BEL	2
NCT02689440	Phase II	Dasatinib + Venetoclax	Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia	Active, not recruiting	USA	0
NCT02709083	Phase II	Dasatinib Nilotinib Imatinib	Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia	Terminated	USA	0
NCT02722668	Phase II	Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin	UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep	Active, not recruiting	USA	0
NCT02727803	Phase II	anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells	Personalized NK Cell Therapy in CBT	Recruiting	USA	0
NCT02730195	Phase II	Pioglitazone	Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia	Terminated	USA	0
NCT02730312	Phase I	Vibecotamab	PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies	Completed	USA	0
NCT02759016	Phase I	BI 836826 + Ibrutinib	Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Who Have Received at Least One Prior Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib	Completed	USA	0
NCT02767063	Phase Ib/II	Avelumab Pioglitazone	Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) (ACTIW)	Unknown status	FRA	0
NCT02782403	Phase Ib/II	Axitinib + Bosutinib	Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia	Terminated	USA	0
NCT02790515	Phase II	Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim	Provision of TCRgammadelta T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation	Active, not recruiting	USA	0
NCT02795520	Phase Ib/II	OTS167	Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia	Terminated	USA	0
NCT02890758	Phase I	Nogapendekin alfa inbakicept	Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803	Completed	USA	0
NCT02890784	Phase III	Dasatinib	Dasatinib Holiday for Improved Tolerability (DasaHIT)	Completed	DEU	0
NCT02906696	Phase II	Bosutinib	Bosutinib Dose-Optimization Study in Chronic Myeloid Leukemia (CML)	Terminated	USA	0
NCT02917720	Phase II	Nilotinib	2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients (NAUT)	Active, not recruiting	NLD \| DEU	0
NCT02923986	Phase Ib/II	BP1001 + Dasatinib	Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS	Withdrawn	USA	0
NCT02930109	Phase Ib/II	Cytarabine + Triciribine	A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia	Completed	USA	0
NCT02960646	Phase I	Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab	Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Completed	USA	0
NCT02973711	Phase Ib/II	Nilotinib + Ruxolitinib	A Phase I/II Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML	Withdrawn	USA	0
NCT03075826	Phase II	Guadecitabine	A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms	Completed	USA	0
NCT03085173	Phase I	EGFRt/19-28z/4-1BBL CAR T cells	A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies	Active, not recruiting	USA	0
NCT03106779	Phase III	Bosutinib Asciminib	Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs	Active, not recruiting	USA \| TUR \| ROU \| NLD \| LBN \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BGR \| AUS \| ARG	6
NCT03193281	Phase II	Imatinib Dasatinib	KISS Study: Kinase Inhibition With Sprycel Start up (KISS)	Active, not recruiting	NZL	0
NCT03267186	Phase II	Ibrutinib	Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant	Completed	USA	0
NCT03326921	Phase I	Fludarabine HA-1 TCR T cells	HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant	Recruiting	USA	0
NCT03386513	Phase Ib/II	IMGN632	Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN	Active, not recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DEU	0
NCT03414450	Phase I	Dasatinib + ETC-1907206	Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies	Withdrawn	USA	1
NCT03459534	Phase III	Radotinib	A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs	Recruiting	TUR	3
NCT03480360	Phase III	Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus	Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression	Active, not recruiting	USA	0
NCT03516279	Phase II	Nilotinib + Pembrolizumab Dasatinib + Pembrolizumab Imatinib + Pembrolizumab	Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease	Recruiting	USA	0
NCT03531736	Phase I	Rituximab Cyclophosphamide + Fludarabine	T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia	Active, not recruiting	USA	0
NCT03573596	Phase II	Dasatinib	Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment (DASTOP2)	Unknown status	SWE \| NOR \| NLD \| FRA \| FIN \| DNK \| DEU	0
NCT03576547	Phase Ib/II	Dexamethasone + Ponatinib + Rituximab + Venetoclax Dexamethasone + Ponatinib + Venetoclax	Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia	Completed	USA	0
NCT03578367	Phase II	Imatinib Nilotinib Asciminib + Imatinib	Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)	Active, not recruiting	USA \| POL \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CAN \| AUT	4
NCT03595917	Phase I	Asciminib + Blinatumomab + Dasatinib + Prednisone	ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML	Recruiting	USA	0
NCT03610971	Phase II	Nilotinib + Ruxolitinib Imatinib + Ruxolitinib Bosutinib + Ruxolitinib Dasatinib + Ruxolitinib	Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors	Recruiting	USA	0
NCT03654768	Phase II	Bosutinib Dasatinib Nilotinib Dasatinib + Ruxolitinib Bosutinib + Ruxolitinib Nilotinib + Ruxolitinib	Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia	Active, not recruiting	USA	0
NCT03674411	Phase II	Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus	Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy	Active, not recruiting	USA	0
NCT03739606	Phase II	Flotetuzumab	Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	Withdrawn		0
NCT03807063	Phase I	Rimiducid Rivogenlecleucel	Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant	Withdrawn	USA	0
NCT03807479	Phase II	Ponatinib	Study in Patients With Chronic Leukemia, Where Previous Therapy Failed, and Who Will be Treated With Ponatinib as Second Line Therapy (PONS)	Terminated	DEU	0
NCT03831776	Phase II	Bosutinib + Ropeginterferon Bosutinib	Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis (BosuPeg)	Recruiting	SWE \| NOR \| FIN \| DNK	0
NCT03874858	Phase II	Nilotinib Asciminib + Nilotinib	De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination (DANTE)	Active, not recruiting	ITA	0
NCT03895671	Phase II	Azacitidine + Ponatinib	PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS (PONAZA)	Recruiting	FRA	0
NCT03906292	Phase II	Asciminib + Nilotinib Asciminib + Imatinib Asciminib + Dasatinib	Frontline Asciminib Combination in Chronic Phase CML (CMLXI)	Active, not recruiting	DEU	0
NCT03934372	Phase Ib/II	Ponatinib	Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors	Recruiting	SWE \| NLD \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU \| BEL	0
NCT04043676	Phase II	Ponatinib	Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia	Unknown status	ESP	0
NCT04070443	Phase II	Imatinib + Ponatinib	Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (TIPI)	Active, not recruiting	FRA	0
NCT04103879	Phase II	ECT-001 cord blood cells Cyclophosphamide + Fludarabine + Thiotepa Tacrolimus Cyclophosphamide + Fludarabine Mycophenolate mofetil	US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia	Active, not recruiting	USA \| NLD	0
NCT04160546	Phase II	Aspirin + Ponatinib	Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP) (ResToP)	Active, not recruiting	ESP	0
NCT04188405	Phase II	Decitabine + Ponatinib + Venetoclax	Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia	Active, not recruiting	USA	0
NCT04216563	Phase II	Asciminib	ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor	Active, not recruiting	USA	0
NCT04258943	Phase Ib/II	Bosutinib	Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia	Active, not recruiting	USA	0
NCT04260022	Phase I	Olverembatinib	Study of HQP1351 in Subjects With Refractory Chronic Myeloid Leukemia (HQP1351CU101)	Recruiting	USA	0
NCT04518644	Expanded access	Nilotinib	Nilotinib, for Patients With CML-CP or CML-AP	No longer available		0
NCT04666259	Phase III	Asciminib	Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation (AIM4CML)	Completed	USA	0
NCT04681105	Phase I	Acetaminophen + Dexamethasone + Diphenhydramine + Flotetuzumab + Ranitidine Dexamethasone + Diphenhydramine + Flotetuzumab + Ibuprofen + Ranitidine	Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies	Active, not recruiting	USA	0
NCT04709731	Phase II	Ponatinib	Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia (CarPAs)	Not yet recruiting	ITA	0
NCT04793399	Phase Ib/II	Atezolizumab + Bosutinib	Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients	Terminated	ESP	0
NCT04835584	Phase Ib/II	Dasatinib + KRT-232 KRT-232 + Nilotinib	KRT-232 and TKI Study in Chronic Myeloid Leukemia	Recruiting	USA \| POL \| ITA \| FRA \| ESP \| CAN	2
NCT04838041	Phase II	Asciminib + Imatinib Asciminib + Dasatinib Asciminib + Nilotinib	Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation	Recruiting	USA	0
NCT04877522	FDA approved	Asciminib Bosutinib Dasatinib Nilotinib Asciminib + Imatinib	Asciminib Roll-over Study	Recruiting	USA \| TUR \| ROU \| POL \| LBN \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| BGR \| AUT \| ARG	9
NCT04925479	Phase Ib/II	Asciminib	Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia	Recruiting	USA \| TUR \| POL \| NLD \| ITA \| HUN \| GRC \| FRA \| DEU	5
NCT04948333	Phase III	Asciminib	Asciminib Treatment Optimization in >= 3rd Line CML-CP.	Active, not recruiting	POL \| ITA \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| AUT \| ARG	5
NCT04955938	Phase I	Enasidenib + Fedratinib Fedratinib + Ivosidenib	A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms	Withdrawn	USA	0
NCT04971226	Phase III	Asciminib Bosutinib Imatinib Dasatinib Nilotinib	A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP	Active, not recruiting	USA \| SWE \| SVK \| NOR \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BGR \| BEL \| AUT \| AUS	8
NCT05007873	Phase II	Dasatinib + Decitabine and Cedazuridine	ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase	Recruiting	USA	0
NCT05016947	Phase I	Dexamethasone + Inotuzumab ozogamicin + Venetoclax	Venetoclax Plus Inotuzumab for B-ALL	Recruiting	USA	0
NCT05143840	Phase II	Asciminib Asciminib + Nilotinib	Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (ALERTCML)	Recruiting	USA	0
NCT05177211	Phase II	Fedratinib	Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)	Active, not recruiting	USA	0
NCT05178342	Phase II	CA-4948	Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 (LUCAS)	Terminated	DEU	0
NCT05304377	Phase I	ELVN-001	A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia (CML)	Recruiting	USA \| FRA \| ESP \| DEU \| CAN \| AUS	1
NCT05362773	Phase I	MGD024	A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies	Recruiting	USA	0
NCT05384587	Phase II	Asciminib	Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (ASC2ESCALATE)	Active, not recruiting	USA	0
NCT05400122	Phase I	Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine	Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer	Recruiting	USA	0
NCT05413915	Phase III	Asciminib + Imatinib Imatinib	Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML	Recruiting	CAN	0
NCT05442515	Phase Ib/II	CD19/CD22 CAR T cells Cyclophosphamide + Fludarabine	CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies	Recruiting	USA	0
NCT05456191	Phase III	Asciminib Nilotinib	A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (>=18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)	Active, not recruiting	USA \| TUR \| SVK \| ROU \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| DEU \| CZE \| CHE \| CAN \| BGR \| ARG	8
NCT05701215	Phase II	Venetoclax	Venetoclax After TKI to Target Persisting Stem Cells in CML (VARIANT)	Recruiting	DEU	0
NCT05823571	Phase I	Itacitinib	Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients	Recruiting	USA	0
NCT06088888	Phase I	TGRX-678	TGRX-678 US Phase I for Subjects With Refractory or Advanced Chronic Myelogenous Leukemia	Recruiting	USA	0
NCT06163430	Phase I	TERN-701	CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia	Not yet recruiting	USA	0
NCT06236724	Phase II	Asciminib	Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.	Recruiting	USA	0
NCT06291987	Phase I	Ivosidenib + Ruxolitinib	Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation (MPN)	Recruiting	USA	0
NCT06401603	Phase I	APG-2575 + Decitabine + Olverembatinib	A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia	Recruiting	USA	0
NCT06423911	Phase III	Bosutinib + Olverembatinib Olverembatinib	Study of Olverembatinib (HQP1351) in Patients With CP-CML (POLARIS-2)	Recruiting	USA	0
NCT06523556	Phase Ib/II	Axatilimab Axatilimab + Azacitidine	Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia	Recruiting	USA	0
NCT06645886	Phase I	Dasatinib + KQB198 KQB198	A Study to Investigate the Safety and Efficacy of KQB198 As Monotherapy and in Combination in Participants with Advanced Hematologic Malignancies	Recruiting	USA	0

ID	DOID:8552
Name	chronic myeloid leukemia
Definition	A myeloid leukemia that is characterized by over production of white blood cells.
Source	DiseaseOntology.org
Alt Ids	DOID:8551 DOID:8606
Path	disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia myeloid leukemia chronic myeloid leukemia

Disease Detail

Contact

Filtering

Sorting